Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Megan E. Capozzi, Richard D. DiMarchi, Matthias H. Tschöp, et al.
Endocrine Reviews (2018) Vol. 39, Iss. 5, pp. 719-738
Open Access | Times Cited: 127

Showing 1-25 of 127 citing articles:

Metabolically Healthy Obesity
Matthias Blüher
Endocrine Reviews (2020) Vol. 41, Iss. 3
Open Access | Times Cited: 725
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism
Fiona M. Gribble, Frank Reimann
Nature Reviews Endocrinology (2019) Vol. 15, Iss. 4, pp. 226-237
Closed Access | Times Cited: 499
Mechanisms controlling pancreatic islet cell function in insulin secretion
Jonathan E. Campbell, Christopher B. Newgard
Nature Reviews Molecular Cell Biology (2021) Vol. 22, Iss. 2, pp. 142-158
Open Access | Times Cited: 440
Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi, Olivia M. Farr, Stergios A. Pοlyzos, et al.
Metabolism (2018) Vol. 92, pp. 170-192
Open Access | Times Cited: 229
Pharmacological treatment of hyperglycemia in type 2 diabetes
Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, Amber L. Beitelshees
Journal of Clinical Investigation (2021) Vol. 131, Iss. 2
Open Access | Times Cited: 181
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coşkun, Shweta Urva, William C. Roell, et al.
Cell Metabolism (2022) Vol. 34, Iss. 9, pp. 1234-1247.e9
Open Access | Times Cited: 158
Glucagon Receptor Signaling and Glucagon Resistance
Lina Janah, Sasha A. S. Kjeldsen, Katrine D. Galsgaard, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 13, pp. 3314-3314
Open Access | Times Cited: 157
Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems
Yining Xu, Neha Shrestha, Véronique Préat, et al.
Journal of Controlled Release (2020) Vol. 322, pp. 486-508
Closed Access | Times Cited: 155
Glucagon Receptor Signaling and Lipid Metabolism
Katrine D. Galsgaard, Jens Pedersen, Filip K. Knop, et al.
Frontiers in Physiology (2019) Vol. 10
Open Access | Times Cited: 153
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 128
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Pharmacological Research (2022) Vol. 186, pp. 106550-106550
Open Access | Times Cited: 114
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, et al.
Molecular Metabolism (2022) Vol. 63, pp. 101533-101533
Open Access | Times Cited: 86
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff, Robert F. Kushner
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 125-139
Open Access | Times Cited: 80
Glucagon lowers glycemia when β cells are active
Megan E. Capozzi, Jacob B. Wait, Jepchumba Koech, et al.
JCI Insight (2019) Vol. 4, Iss. 16
Open Access | Times Cited: 136
The Liver–α-Cell Axis and Type 2 Diabetes
Nicolai J. Wewer Albrechtsen, Jens Pedersen, Katrine D. Galsgaard, et al.
Endocrine Reviews (2019) Vol. 40, Iss. 5, pp. 1353-1366
Open Access | Times Cited: 133
Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
Brian Finan, Megan E. Capozzi, Jonathan E. Campbell
Diabetes (2019) Vol. 69, Iss. 4, pp. 532-541
Open Access | Times Cited: 101
Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives
Walter Cabri, Paolo Cantelmi, Dario Corbisiero, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 93
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Jonathan E. Campbell
Molecular Metabolism (2020) Vol. 46, pp. 101139-101139
Open Access | Times Cited: 86
Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
Valentina Pirro, Kenneth D. Roth, Yanzhu Lin, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 2, pp. 363-378
Open Access | Times Cited: 83
The past, present, and future physiology and pharmacology of glucagon
Megan E. Capozzi, David A. D’Alessio, Jonathan E. Campbell
Cell Metabolism (2022) Vol. 34, Iss. 11, pp. 1654-1674
Open Access | Times Cited: 54
Tirzepatide: A Systematic Update
Imma Forzano, Fahimeh Varzideh, Roberta Avvisato, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14631-14631
Open Access | Times Cited: 48
Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes?
Zaman Mirzadeh, Chelsea L. Faber, Michael W. Schwartz
The Annual Review of Pharmacology and Toxicology (2022) Vol. 62, Iss. 1, pp. 55-84
Open Access | Times Cited: 39
Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
Martin Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, et al.
Molecular Metabolism (2023) Vol. 78, pp. 101801-101801
Open Access | Times Cited: 24
The role of GIP in α-cells and glucagon secretion
Kimberley El, Jonathan E. Campbell
Peptides (2019) Vol. 125, pp. 170213-170213
Open Access | Times Cited: 74
The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice
Jacqueline L. Beaudry, Kiran Deep Kaur, Elodie M. Varin, et al.
Molecular Metabolism (2019) Vol. 22, pp. 37-48
Open Access | Times Cited: 68
Page 1 - Next Page

Scroll to top